Evidence map›Paper›PMID 39809737›Full record

ArticleNature communications2025

Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa.

Nell Hirt, Enzo Manchon, Qian Chen, Clara Delaroque, Aurelien Corneau, Patrice Hemon, Safaa Saker-Delye, Pauline Bataille, Jean-David Bouaziz, Emmanuelle Bourrat and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nell Hirt *National Institute of Health and Medical Research (INSERM) UMRS-976 HIPI, Paris Cité University, Saint-Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0003-2840-4886
Enzo Manchon *National Institute of Health and Medical Research (INSERM) UMRS-976 HIPI, Paris Cité University, Saint-Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0001-6699-9978
Qian ChenBoston Childrens Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Clara DelaroqueINSERM U1016, The National Centre for Scientific Research (CNRS) UMR 8104, Paris Cité University, 75014, Paris, France.
Aurelien CorneauPitié-Salpêtrière Cytometry, UMS037, Sorbonne University, 75013, Paris, France.
Patrice HemonLBAI, INSERM UMR1227, Brest University, 29200, Brest, France.ORCID http://orcid.org/0000-0002-2244-5321
Safaa Saker-DelyeGenethon, 91000, Every-Courcouronnes, France.
Pauline BatailleDermatology Department, AP-HP, Saint-Louis Hospital, 75010, Paris, France.
Jean-David BouazizNational Institute of Health and Medical Research (INSERM) UMRS-976 HIPI, Paris Cité University, Saint-Louis Hospital, 75010, Paris, France.
Emmanuelle BourratDermatology Department, AP-HP, Saint-Louis Hospital, 75010, Paris, France.ORCID http://orcid.org/0000-0001-5375-738X
Alain HovnanianLaboratory of Genetic Skin Diseases, Imagine Institute, Paris Cité University, INSERM UMR 1163, 75015, Paris, France.ORCID http://orcid.org/0000-0003-3412-7512
Helene Le BuanecNational Institute of Health and Medical Research (INSERM) UMRS-976 HIPI, Paris Cité University, Saint-Louis Hospital, 75010, Paris, France.
Fawzi AoudjitDivision of Immune and Infectious Diseases, CHU de Quebec Research Centre, Department of Microbiology-Infectiology and Immunology, Faculty of Medicine, Laval University, Quebec City, QC, Canada.
Hicham El CostaInstitute for Infectious and Inflammatory Diseases, CNRS UMR5051, INSERM UMR1291, Toulouse III University, 31059, Toulouse, France.ORCID http://orcid.org/0000-0001-8889-9759
Nabila Jabrane-FerratInstitute for Infectious and Inflammatory Diseases, CNRS UMR5051, INSERM UMR1291, Toulouse III University, 31059, Toulouse, France.ORCID http://orcid.org/0000-0003-4809-7836
Reem Al-DaccakNational Institute of Health and Medical Research (INSERM) UMRS-976 HIPI, Paris Cité University, Saint-Louis Hospital, 75010, Paris, France. reem.al-daccak@inserm.fr.ORCID http://orcid.org/0000-0002-6146-2845

Funding

Agence Nationale de la Recherche (French National Research Agency) MetaboHUB-ANR-11-INBS-0010
6 · The paper itself

Abstract

Endotypes are characterized by the immunological, inflammatory, metabolic, and remodelling pathways that explain the mechanisms underlying the clinical presentation (phenotype) of a disease. Recessive dystrophic epidermolysis bullosa (RDEB) is a severe blistering disease caused by COL7A1 pathogenic variants. Although underscored by animal studies, the endotypes of human RDEB are poorly understood. To fill this gap, we apply systems immunology approaches using single-cell high-dimensional techniques to capture the signature of peripheral immune cells and the diversity of metabolic profiles in RDEB adults, sampled outside of any opportunistic infection and active cancer. Our study, demonstrates the particular inflammation and immunity characteristics of RDEB adults, with activated / effector T and dysfunctional natural killer cell signatures, concomitant with an overall pro-inflammatory lipid signature. Artificial intelligence prediction models and principal component analysis stress that RDEB is not solely confined to cutaneous issues but has complex systemic endotypes marked by immune dysregulation and hyperinflammation. By characterising the phenotype-endotype association in RDEB adults, our study lays the groundwork for translational interventions that could by lessening inflammation, alleviate the everlasting suffering of RDEB patients, while awaiting curative genetic therapies.

Indexed as

Epidermolysis Bullosa DystrophicaAdultCollagen Type VIIFemaleHumansImmunoinformaticsInflammationKiller Cells, NaturalMaleMiddle AgedPhenotypeSingle-Cell AnalysisSkinSystems BiologyYoung AdultCOL7A1 protein, humanCollagen Type VII

Identifiers

PMID39809737
PMCPMC11733305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.